A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Main Authors: | Pacey, S, Blackhall, F, Garcia-Corbacho, J, Lipplaa, A, Fusi, A, Kumar, S, Hategan, M, Derham, J, Laviste, G, Halford, S, Foxton, C, McLeod, R, Wan, S, Talbot, D |
---|---|
Format: | Conference item |
Published: |
Oxford University Press
2016
|
Similar Items
-
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
by: Kirkwood, J, et al.
Published: (2012) -
Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment
by: Xiaohang Zheng, et al.
Published: (2022-09-01) -
Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review
by: Michele Basilicata, et al.
Published: (2024-01-01) -
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
by: Brave, SR, et al.
Published: (2011) -
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration
by: Meredith, Erik L., et al.
Published: (2016)